Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.43 |
| ▸ | JAK2 | O60674 | 11/20 | 0.43 |
| ▸ | TYK2 | P29597 | 5/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276523 | 0.97 | JAK1 (0.46) | JAK1JAK2TYK2JAK3SFRP1 | |
| SCHEMBL2277381 | 0.95 | JAK1 (0.47) | JAK1JAK2TYK2JAK3USP30 | |
| SCHEMBL2280324 | 0.95 | JAK1 (0.45) | JAK1JAK2TYK2JAK3SFRP1 | |
| SCHEMBL2276073 | 0.95 | JAK1 (0.44) | JAK1JAK2TYK2JAK3MET | |
| SCHEMBL2277886 | 0.91 | JAK1 (0.43) | JAK1JAK2TYK2JAK3USP30 | |
| SCHEMBL2277901 | 0.91 | JAK1 (0.43) | JAK1JAK2TYK2JAK3USP30 | |
| SCHEMBL2274345 | 0.88 | JAK1 (0.46) | JAK1JAK2TYK2JAK3USP30 | |
| SCHEMBL9959458 | 0.85 | JAK1 (0.47) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2275417 | 0.84 | JAK1 (0.48) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2276274 | 0.84 | JAK2 (0.51) | JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | JAK1 434/4885JAK2 122/4885TYK2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.